{"id":55947,"date":"2023-04-18T15:04:18","date_gmt":"2023-04-18T13:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/"},"modified":"2023-04-18T15:04:18","modified_gmt":"2023-04-18T13:04:18","slug":"genexa-receives-its-first-patent-for-agave-based-medicines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/","title":{"rendered":"Genexa Receives Its First Patent for Agave-Based Medicines"},"content":{"rendered":"
\n

\nThe patent is for a stable pharmaceutical formulation or suspension that has a pharmaceutical active agent, agave and a dilutant.<\/i><\/p>\n

ATLANTA–(BUSINESS WIRE)–Genexa, the first and only clean over-the-counter (OTC) medicine company making medicines for the entire family, announced today that the company has been granted a patent for its drinkable agave-based medicines containing acetaminophen, applicable to its best-selling Infants\u2019 Pain & Fever<\/i> and Kids\u2019 Pain & Fever<\/i> products. Genexa makes medicine using the same effective active ingredients as category leaders such as Tylenol\u00ae, Benadryl\u00ae, Mucinex\u00ae and Robitussin\u00ae, but differentiates itself from its competitors by refusing to use any artificial inactive ingredients \u2013 no artificial sweeteners, dyes, or common allergens. Artificial fillers typically comprise more than half of what is ingested each time traditional medicines are used.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis patent validates Genexa\u2019s innovative approach to the OTC medicine market. The company has numerous additional patent applications pending for formulations containing active pharmaceutical ingredients for treating pain, allergy, cold and flu, sleep, and other symptoms, both with and without acetaminophen. The company anticipates receiving additional patents within the coming months.<\/p>\n

\n\u201cWe are excited by the acceptance of our first patent and this milestone for a new category\u2014clean medicine,\u201d said Genexa Co-Founder and President, Max Spielberg. \u201cWe are intent on developing this platform so that one day \u2018clean medicine\u2019 is the standard for all medicines.\u201d<\/p>\n

\nGenexa\u2019s products are available at over 60,000 retailers nationwide including Walmart, Walgreens, Rite Aid, CVS, Whole Foods and Sprouts, as well as online at Genexa.com and Amazon.<\/p>\n

\nAll of Genexa\u2019s products are manufactured according to FDA guidelines and are Non-GMO Project Verified and gluten-free. Many are certified organic and vegan as well. As a Certified B-Corporation, Genexa is committed to using business as a force for good, meeting rigorous standards of social and environmental performance, accountability, and transparency.<\/p>\n

\nFor more information, visit Genexa.com<\/a>.<\/p>\n

\nABOUT GENEXA:<\/b><\/p>\n

\nFounded by two dads on a mission to revolutionize the medicine aisle, Genexa makes medicine with the same active ingredients people need, but without the artificial ones they don\u2019t. In its commitment to putting People Over Everything\u00ae, Genexa is finally providing real choices for families. All of Genexa\u2019s products are made to the highest standards of medicine with no dyes or artificial sweeteners, common allergens, or unnecessary artificial ingredients. It\u2019s real medicine, made clean. Learn more about how they are putting people over everything at Genexa.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nSuperjuice on behalf of Genexa: Alison Blue
\n
201.709.4331, alison@wearesuperjuice.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The patent is for a stable pharmaceutical formulation or suspension that has a pharmaceutical active agent, agave and a dilutant. ATLANTA–(BUSINESS WIRE)–Genexa, the first and only clean over-the-counter (OTC) medicine company making medicines for the entire family, announced today that the company has been granted a patent for its drinkable agave-based medicines containing acetaminophen, applicable … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55947","6":"format-standard","7":"category-industry"},"yoast_head":"\nGenexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The patent is for a stable pharmaceutical formulation or suspension that has a pharmaceutical active agent, agave and a dilutant. ATLANTA–(BUSINESS WIRE)–Genexa, the first and only clean over-the-counter (OTC) medicine company making medicines for the entire family, announced today that the company has been granted a patent for its drinkable agave-based medicines containing acetaminophen, applicable ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T13:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Genexa Receives Its First Patent for Agave-Based Medicines\",\"datePublished\":\"2023-04-18T13:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/\"},\"wordCount\":421,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005228\\\/en\\\/1765442\\\/21\\\/Kids_Pain_OTCs_v2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/\",\"name\":\"Genexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005228\\\/en\\\/1765442\\\/21\\\/Kids_Pain_OTCs_v2.jpg\",\"datePublished\":\"2023-04-18T13:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005228\\\/en\\\/1765442\\\/21\\\/Kids_Pain_OTCs_v2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230418005228\\\/en\\\/1765442\\\/21\\\/Kids_Pain_OTCs_v2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genexa-receives-its-first-patent-for-agave-based-medicines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genexa Receives Its First Patent for Agave-Based Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/","og_locale":"en_US","og_type":"article","og_title":"Genexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend","og_description":"The patent is for a stable pharmaceutical formulation or suspension that has a pharmaceutical active agent, agave and a dilutant. ATLANTA–(BUSINESS WIRE)–Genexa, the first and only clean over-the-counter (OTC) medicine company making medicines for the entire family, announced today that the company has been granted a patent for its drinkable agave-based medicines containing acetaminophen, applicable ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-18T13:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Genexa Receives Its First Patent for Agave-Based Medicines","datePublished":"2023-04-18T13:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/"},"wordCount":421,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/","url":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/","name":"Genexa Receives Its First Patent for Agave-Based Medicines - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg","datePublished":"2023-04-18T13:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230418005228\/en\/1765442\/21\/Kids_Pain_OTCs_v2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/genexa-receives-its-first-patent-for-agave-based-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Genexa Receives Its First Patent for Agave-Based Medicines"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55947"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55947\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}